Pulmonology Medical News about Lung Neoplasms Pemetrexed

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer
Therapeutics and Clinical Risk Management, 09/29/09

Ricciardi S et al. – Pemetrexed is a new cytotoxic agent that is a standard of care for the second–line treatment of non–small cell lung cancer (NSCLC) and in combination with cisplatin in treatment of malignat pleural mesothelioma. It has been studied in numerous phase II and III trials in combination with different drugs or as single agent. Recently, pemetrexed has been approved in combination with cisplatin for the first–line treatment of patients with locally advanced or metastatic NSCLC other than squamous cell histology. The toxicity is acceptable and similar to that of other NSCLC regimens. The postinduction maintenance therapy with pemetrexed is being evaluated in a phase III, double–blind, placebo–controlled study.

<< Previous
Anxiety and Depression in Cystic Fibrosis

Next >>
Burkholderia cepacia Complex: Impact on the Cystic Fibrosis Lung...